Table 3.
Secondary outcomes of treatment at months 6 and 12 of the study
| Variables | CYC (N=32) n (%) |
EC-MPS (N=27) n (%) |
Unadjusted percentage difference between groups* % (95% CI) |
p Value | Adjusted percentage difference between groups* % (95% CI) |
p Value |
|---|---|---|---|---|---|---|
| Nephrotic syndrome | ||||||
| At 6th month | 8/25 (32.00) | 9/25 (36.00) | −4.00 (−30.2 to 22.2) | 0.77 | 7.93 (−11.1 to 27.0)† | 0.42 |
| At 12th month | 6/25 (24.00) | 6/24 (25.00) | −1.00 (−25.1 to 23.1) | 0.94 | 7.60 (−11.3 to 26.5)† | 0.43 |
| Mean changes of eGFR (mL/min/1.73 m2) | ||||||
| 6th month minus baseline‡ (95% CI) | −0.04 (−10.69 to 10.62) | +7.51 (−2.52 to 17.53) | 0.29 | NA | NA | |
| 12th month minus baseline‡ (95% CI) | +8.52 (−0.34 to 17.38) | +2.91 (−5.64 to 11.47) | 0.35 | NA | NA | |
| Serious adverse events | ||||||
| 0–12th month | 5/32 (15.63) | 2/27 (7.41) | 8.22 (−7.8 to 24.2) | 0.31 | 9.93 (−3.5 to 23.4)† | 0.15 |
| Serious fatal and non-fatal infections | ||||||
| 0–12th month | 5/32 (15.63) | 1/27 (3.70) | 11.92 (−2.5 to 26.4) | 0.11 | 13.35 (0.3 to 26.4)† | 0.046 |
*The difference is shown as the value for group 1 minus the value for group 2.
†Adjusted for baseline nephrotic-range proteinuria.
‡Compare eGFR with the baseline (at study entry).
CYC, cyclophosphamide; EC-MPS, enteric-coated mycophenolate sodium; eGFR, estimated glomerular filtration rate; NA, not applicable.